Drug Profile
Research programme: dihydrophthalazine antifolates - Basilea Pharmaceutica
Alternative Names: BAL0030543; BAL0030544; BAL0030545; BAL30543; BAL30544; BAL30545Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Basilea Pharmaceutica
- Class Phthalazines
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Enterococcal infections; Staphylococcal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Enterococcal-infections in Switzerland
- 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections in Switzerland
- 30 Apr 2009 Preclinical pharmacodynamics data in Staphylococcal infections released by Basilea Pharmaceutica